-
Yescarta was awarded an orphan drug for four types of lymphoma
Time of Update: 2021-02-14
Daiichi Sankyo, a Japanese pharmaceutical company, recently announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has awarded CAR-T cell therapy axicabtagene ciloleucel (formerly known as KTE-C19) to treat diffuse large B-cell lymphoma (D LBCL), primary vertical (thymus) large B-cell lymphoma (PMBCL), high-level B-cell lymphoma (HGBL), transformational fiery lymphoma (TFL) orphan drug eligibility, the above four types of lymphoma are invasive non-Hodgkin lymphoma (NHL).
-
Anti-cancer drugs combined with artemisinin, two-pronged attack on drug-resistant malaria parasites!
Time of Update: 2021-02-14
Leann Tilley, a malaria researcher at the University of Melbourne, said: "The double-killing effect means that the combination of artemisinin and another cancer chemotherapy drug targeting proteases to enhance artemisinin activity can effectively restore artemisinin's ability to fight artemisinin-resistant pathogens.
-
First oral CGRP-subject antagonist migraine drug! El Jian ubrogepant will submit a listing application in early 2019:
Time of Update: 2021-02-14
Allergan recently announced that it has completed two clinical studies of ubrogepant for acute migraine treatment and has obtained positive safety and tolerance data. first study (UBR-MD-04) assessed
-
Takeda's next-generation targeted drug, Arunbrig, has been approved by THECHMP
Time of Update: 2021-02-14
The study, conducted in patients with local late stage or metastasis APK-NSCLC who had not previously been treated with ALC inhibitors, assessed the efficacy and safety of Alunbrig (90 mg once a day during the import period and 180 mg once a day after the introduction period) relative to Xalkori (250 mg, 2 times a day) for first-line treatment.
-
New drug for high potassiumemia! AstraZeneta's Lokelma performed strongly in Asian patients to reduce and maintain normal blood potassium levels:
Time of Update: 2021-02-14
AstraZenecon's vice president of global drug development and head of cardiovascular, kidney and metabolic research, Elisabeth Björk, said the positive results of the HARMONIZE Global study added to the growing body of evidence supporting Lokelma's treatment for adult high potassiumemia, a serious disease associated with chronic kidney disease, heart failure and diabetes, and the use of nephrogen-angiosin-aldosterone system inhibitors.
-
Hepatitis B super heavy news! Vemlidy (TAF), the safest new drug in Gilead's history, has been approved by China
Time of Update: 2021-02-14
U.S. pharmaceutical giant Gilead recently announced that the antiviral drug Vemlidy (tenofovir alafenamide, TAF, tinofovir phenolamine fumaric acid) has been approved by China's State Drug Administration (NMPA) as a daily drug for the treatment of adults and adolescents with chronic hepatitis B (HBV) (12 years and older, weighing ≥35 kg).
-
New drug for short bowel syndrome! Shire's Gattex (Tydioglutide) treatment of paediatric adaptive disorders has entered the formal U.S.:
Time of Update: 2021-02-14
The sNDA applied for approval to expand the adaptation of Gattex injections for the treatment of pediatric patients (1-17 years of age) who rely on intestinal support for short bowel syndrome (SBS).
-
The new study uses artificial intelligence to determine the molecular structure of drugs
Time of Update: 2021-02-14
Swiss researchers have developed a new way to determine the molecular structure of drugs using artificial intelligence technology, which is much more efficient than existing methods and helps the pharmaceutical industry develop new drugs.
-
New progress has been made in the study of the anti-diabetic mechanism of metformin
Time of Update: 2021-02-14
The findings were published online October 24, 2018 in the journal Cell under the title "Changes of cell biochemical states are revealed in protein homomeric complex dynamics." to confirm that metformin appears to make cells appear to lack the necessary mineral iron, the researchers used a new method to simultaneously detect how all bio-chemical processes in cells respond to the presence of a drug.
-
Use the addictive nature of pancreatic cancer to develop new anti-cancer therapies
Time of Update: 2021-02-14
Cancer cells are often described as "bad" or "metastatic" cells, and recent research by scientists at cold spring harbor laboratories in the United States has found that in some of the deadliest cases
-
A new CAR T system that targets brain tumors, making them nowhere to run
Time of Update: 2021-02-14
Through animal studies, researchers found that the cytotoxic HS T cells had a very strong ability to penetrate into brain tumor tissue after intravenous injection, showing strong anti-cancer activity without entering normal brain tissue or other tissues of the body causing toxic side effects.
-
Extracellular substations affect cancer metastasis by regulating sugar metabolism
Time of Update: 2021-02-14
By analyzing the patient's breast cancer tissue and the genes in the breast cancer cell line that affect glucose metabolism, the researchers made a startling discovery: one of the genes closely related to the high-speed metabolism of glucose is a subject of hyalurony acid, the core component of the extracellular substate.
-
The gospel of AIDS! GlaxoSmithKline's world's first two-in-one HIV compound, Juluca, has been approved by Japan
Time of Update: 2021-02-14
Recently, the company announced that the two-in-one HIV compound new drug Juluca (dolutegravir/rilpivirine, dotiravir/lippivirin, 50mg/25mg tablet) has been approved by the Ministry of Health, Labour and Welfare (MHLW) as a maintenance therapy for long-term treatment of HIV-1 adults who have achieved viral suppression.
-
Lilly Emgality has been approved by the FDA as the third CGRP targeted drug to hit the market
Time of Update: 2021-02-14
Emgality will provide a monthly, self-injected subsoil injection drug for adult migraine patients, which is strictly prohibited for patients with severe allergies to galcanezumab-gnlm or any exfusion.
As part of Lilly's Patient Support Program, patients with commercial insurance receive up to 12 months of Emgality treatment free of charge.
-
VistaGen's new oral NMDA-agent antagonist AV-101 has won the FDA's second fast-track status
Time of Update: 2021-02-14
Recently, the company announced that the U.S. Food and Drug Administration (FDA) has granted the experimental drug AV-101 as a non-opioid non-sedative for the treatment of neuropathic pain fast-track status.
-
New standards for first-line treatment of liver cancer! Wessa and Merca East launched Lenvima (Le Weima) in Japan, China in early September has:
Time of Update: 2021-02-14
In addition, Lenvima has been approved for treatment of hepatocellular carcinoma (HCC) in Japan, the United States, Europe, China and other countries and regions.
-
New yew alcohol preparations! Oasmia's Apealea (Yew alcohol beam) has been approved by the European Union to treat relapsed eggs:
Time of Update: 2021-02-14
Recently, the company announced that the European Commission (EC) has approved the treatment of Apealea (paclitaxel micellar, yew alcohol beam), a joint carp platinum for the first recurrence of platinum-sensitive epithelyl ovarian cancer, primary peritina cancer, fallopian tube cancer in adult patients.
-
Lilly migraine new drug Emgality has been approved by the European Union as Europe's third CGRP targeted drug
Time of Update: 2021-02-14
It's worth noting that in the middle of this month, Lilly also submitted to the FDA a new drug application for the oral migraine drug lasmiditan (NDA) for acute treatment of migraines accompanied or not accompanied by pre-eclampsia in adult patients.
-
Second-line new drug for advanced liver cancer! Ipsos' targeted cancer drug Cabometyx has been approved by the European Union
Time of Update: 2021-02-14
French pharmaceutical company Ipsen recently announced that the European Commission (EC) has approved a new adaptation of the target cancer drug Cabozantinix 20mg, 40mg and 60mg tablets as a single-drug therapy for adult patients with advanced hepatocellular carcinoma (HCC) who have previously been treated with sorafenib.
-
Novardo Promacta, the first new drug in a decade, has been approved as a first-line therapy
Time of Update: 2021-02-14
Novarca has announced that the U.S. Food and Drug Administration (FDA) has expanded Promacta's adaptation labeling application to support the drug's use in connection with standard immunosuppressive therapy (IST) for first-line treatment in adults with regenerative anemia and pediatric patients 2 years and older.
![9-[1,1'-biphenyl]-4-yl-3,3'-Bi-9H-carbazole](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
